Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
New England Journal of Medicine · 22.02.2024 · 390 (8) · 701-711
DOI: 10.1056/nejmoa2310392 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 22.02.2024. Verfasst von Gregory W Albers und 23 weiteren Autor:innen. Beteiligte Einrichtung: From Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, Palo Alto (G.W.A., N.E.S., M.G.L.), Genentech, S…. Hauptthemen laut MEDLINE: Brain Ischemia, Perfusion Imaging, Tenecteplase, Thrombectomy. Die Arbeit wurde bisher 204-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Genentech, F. Hoffmann-La Roche.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to 25 mg) with placebo administered 4.5 to 24 hours after the time that the patient was last known to be well. Patients had to have evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging. The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at day 90. Safety outcomes included death and symptomatic intracranial hemorrhage. RESULTS: The trial enrolled 458 patients, 77.3% of whom subsequently underwent thrombectomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo. The median time between the time the patient was last known to be well and randomization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the placebo group. The median score on the modified Rankin scale at 90 days was 3 in each group. The adjusted common odds ratio for the distribution of scores on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% confidence interval, 0.82 to 1.57; P = 0.45). In the safety population, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and the incidence of symptomatic intracranial hemorrhage was 3.2% and 2.3%, respectively. CONCLUSIONS: Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, Palo Alto (G.W.A., N.E.S., M.G.L.), Genentech, South San Francisco (B.P., M.Y., L.M., X.-Y.L., G.A.R.), and the Depart…
Förderung
- Genentech
- F. Hoffmann-La Roche
Zitieren
APA
Albers, G. W., Jumaa, M., Purdon, B., Zaidi, S. F., Streib, C., Shuaib, A., Sangha, N., Kim, M., Froehler, M. T., Schwartz, N. E., Clark, W. M., Kircher, C. E., Yang, M., Massaro, L., Lu, X. Y., Rippon, G. A., Broderick, J. P., Butcher, K., Lansberg, M. G., …, & TIMELESS Investigators (2024). Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. New England Journal of Medicine, 390(8), 701-711. https://doi.org/10.1056/nejmoa2310392
Vancouver
Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. New England Journal of Medicine. 2024;390(8):701-711. doi:10.1056/nejmoa2310392
BibTeX
@article{Albers2024,
author = {Albers, Gregory W and Jumaa, Mouhammad and Purdon, Barbara and Zaidi, Syed F and Streib, Christopher and Shuaib, Ashfaq and Sangha, Navdeep and Kim, Minjee and Froehler, Michael T and Schwartz, Neil E and Clark, Wayne M and Kircher, Charles E and Yang, Ming and Massaro, Lori and Lu, Xiao-Yu and Rippon, Gregory A and Broderick, Joseph P and Butcher, Ken and Lansberg, Maarten G and Liebeskind, David S and Nouh, Amre and Schwamm, Lee H and Campbell, Bruce C V and TIMELESS Investigators, TIMELESS Investigators},
title = {Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {8},
pages = {701--711},
doi = {10.1056/nejmoa2310392}
}
EUVIMED